Pharmaceutical Executive-08-01-2021

Changes necessitated by COVID will drive unprecedented transformation of industry.

COVID-19 may be the latest challenge to primary care physicians, but it’s just one of many threatening the profession, including the increased focus on specialty drug markets—if PCPs are left out of the equation.

The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.

Examining why the cost and administration of these treatments are well suited to managed entry agreements—and which approach to MEA may prove to be the most commercially viable for manufacturers.

The BCG Market Access Roundtable presents an updated view of its access competencies framework first published five years ago.

A look at how VBC agreements between drug manufacturers and payers—which reimburse for pre-specified treatment outcomes—have measured up so far in reducing healthcare costs, and the opportunities still untapped to drive true value for both sides and the patients they serve.

Biopharma leaders and experts gather to discuss the future of pharma collaboration and tackling critical public health needs—together.

Ester Banque, senior vice president and head of Intercontinental Commercial at Bristol Myers Squibb, talks purpose and perseverance—both in her own career journey and her group’s mission to topple barriers to drug access in diverse and hard-to-reach regions.

Initial coverage discussions put the focus on three key factors.

But could there be a shift in momentum?

Accelerated implementation of AI platforms among pharma sales teams has highlighted the importance of the human factor.

For leaders, shifting mindsets and altering dynamics can help.

Report claims an imbalance in influence of tech-transfer decisions.

Sweeping competition initiative drills in on cost reduction.

Looking Back at 2003–2006.

Still plenty to learn about the virus even after year-plus long pandemic

Collaboration shines through year of COVID.

Click the title above for a link to open the Pharmaceutical Executive August 2021 issue in an interactive PDF format.